HUM
30
3
BF.B
57
7
FMC
36
3
THC
61
3
CMG
50
-6
AN
49
2
ADSK
65
-2
VRSN
50
-5
CRM
50
-5
SWN
70
3
INTC
37
-4
PLD
51
-5
WU
16
2
ICE
64
-5
CHRW
48
8
PAYX
53
-4
O
35
-2
AAL
47
-3
FRT
41
-2
V
64
-4
HUM
30
3
BF.B
57
7
FMC
36
3
THC
61
3
CMG
50
-6
AN
49
2
ADSK
65
-2
VRSN
50
-5
CRM
50
-5
SWN
70
3
INTC
37
-4
PLD
51
-5
WU
16
2
ICE
64
-5
CHRW
48
8
PAYX
53
-4
O
35
-2
AAL
47
-3
FRT
41
-2
V
64
-4
Financhill
Back

Black Diamond Therapeutics Quote, Financials, Valuation and Earnings

"EarnPhone": The Investment Hidden in Plain Sight

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
40

BDTX
Black Diamond Therapeutics

Last Price:
4.79
Seasonality Move:
-21.92%

7 Day Trial

ALL ACCESS PASS

$ 7

Hint at where the next big move in the market will be this month

Spot the next big move with this free book from a hedge fund manager

Black Diamond Therapeutics Price Quote

$4.79
+0.06 (+1.27%)
(Updated: September 19, 2024 at 6:55 PM ET)

Black Diamond Therapeutics Key Stats

Sell
40
Black Diamond Therapeutics (BDTX) is a Sell
Day range:
$4.51 - $4.89
52-week range:
$1.62 - $7.66
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
2.41%
Volume:
1.1M
Avg. volume:
591.6K
1-year change:
35.14%
Market cap:
$267.3M
Revenue:
$0
EPS:
$-1.5

How Much Does Black Diamond Therapeutics Make?

Data Unavailable

Is Black Diamond Therapeutics Growing As A Company?

Data Unavailable

Black Diamond Therapeutics Stock Price Performance

What Is Black Diamond Therapeutics 52-Week High & Low?

Black Diamond Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Black Diamond Therapeutics?

Is Black Diamond Therapeutics Cash Flow Positive?

  • What Is BDTX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$68.2M
  • What Is Black Diamond Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $97.4M
  • What Is Black Diamond Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$38.6M

Black Diamond Therapeutics Return On Invested Capital

Data Unavailable

Black Diamond Therapeutics Earnings Date & Stock Price

Black Diamond Therapeutics Competitors

Black Diamond Therapeutics Dividend Yield

Black Diamond Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 6.74%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 13.83
Upside from Last Price: 192.46%

Major Shareholders

  • How many BDTX shares are owned by institutional investors?
    94.5M BDTX shares are owned by institutional investors
  • How many BDTX shares are owned by insiders?
    1.2M BDTX shares are owned by insiders